1. Abernethy DR, Burckart GJ (2010) Pediatric dose selection. Clin Pharmacol Ther 87(3):270–271
2. Anderson BJ, Holford NH (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303–332
3. Arndt C, Hawkins D, Anderson JR, Breitfeld P, Womer R, Meyer W (2004) Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. J Clin Oncol 22(10):1894–1901
4. Barrett JS, Patel D, Jayaraman B, Narayan M, Zuppa A (2008a) Key performance indicators for the assessment of pediatric pharmacotherapeutic guidance. J Pediatr Pharmacol Ther 13:141–155
5. Barrett JS, Mitchell LG, Patel D, Cox P, Vegh P, Castillo M et al (2008b) A population-based analysis of dalteparin pharmacokinetics in pediatric patients at risk for thromboembolic events. J Clin Pharmacol 48(9):1107